Alzheimer’s patients and their loved ones have a renewed sense of hope now that the U.S. Food & Drug Administration approved the first Alzheimer’s drug in nearly two decades.

Alzheimer’s patients and their loved ones have a renewed sense of hope now that the U.S. Food & Drug Administration approved the first Alzheimer’s drug in nearly two decades.

Researchers identified sildenafil, known commercially as Viagra, as a promising candidate for treating Alzheimer’s disease. Leveraging artificial intelligence the team analyzed vast amounts of data, including insurance claims and brain cell observations, to highlight sildenafil’s potential benefits in reducing Alzheimer’s prevalence and neurotoxic proteins.

Most ARIA cases are mild, but some have been fatal

Recently approved disease-modifying treatments for Alzheimer's disease have created a sudden demand, but these and other drugs in the pipeline are not for all patients with clinical Alzheimer's symptoms, experts said.

Looking ahead to 2024 and beyond: "There is so much more to be done"

Over the past year, the field has experienced another significant leap of growth, powered by advances in translational research and capped off by the approval of lecanemab (Leqembi; Eisai), the first traditionally approved therapy in nearly two decades.

After decades of failed trials, ineffective drugs and billions of dollars spent, a new frontier of shots offer a glimmer of hope for current and future sufferers of the cruel condition that affects 5.8million Americans.

The positive results are expected to form the basis for further development of Lomecel-B as a potential treatment for mild AD

Neurologists at the biggest Alzheimer's research meeting in the US experienced something this week they hadn't in years: optimism.

Neurologists at the biggest Alzheimer’s research meeting in the US experienced something this week they hadn’t in years: optimism.

As a neurologist with more than 30 years in the field of Alzheimer’s disease, I have had many heartbreaking conversations with patients and their loved ones. More than 6 million people in America are living with Alzheimer’s disease, and that staggering number is expected to double within the next 30 years unless there is a change. However, I am more optimistic about that change and physicians’ ability to slow the course of this devastating illness than I have ever been in the past.